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Percutaneous Coronary Revascularization Reduces
Plasma N-Terminal Pro-B-Type Natriuretic Peptide
Concentration in Stable Coronary Artery Disease
Samuel J. McClure, MBCHB, MRCP,* Scott Gall, MBCHB, MRCP,*
Clyde B. Schechter, MA, MD, FACPM,† Mark Kearney, MBCHB, MRCP, MD,‡
Azfar G. Zaman, BSC, MBCHB, MD, FRCP*§
Newcastle-upon-Tyne and Leeds, United Kingdom; and Bronx, New York
Objectives The purpose of this work was to assess the effect of percutaneous coronary revascularization (PCR) on plasma
N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration.
Background Left ventricular (LV) dysfunction is associated with increased plasma natriuretic peptide concentrations. The
effect of ischemia resolution on plasma natriuretic peptide is not known.
Methods Twenty-six patients with stable angina, normal LV systolic function, and isolated stenoses of the left anterior de-
scending (LAD) coronary artery were studied. All patients had angiographically and physiologically significant
lesions defined by cine-angiography and intracoronary pressure wire.
Results After revascularization, 24 patients demonstrated significant decrease in mean plasma NT-proBNP 8 weeks af-
ter PCR (from 177.2  190.8 pg/ml to 105.0  92.4 pg/ml, p  0.03). The mean decrease in log NT-proBNP
was 0.533, corresponding to geometric mean decrease of NT-proBNP by a factor of 59% (95% confidence inter-
val 48.2% to 71.4%, p  0.00005). Reduction in NT-proBNP was independent of change in LV systolic function.
Conclusions This study demonstrates that removal of fixed LAD stenosis reduces plasma NT-proBNP concentration. This has
implications for interpretation of natriuretic peptide levels in clinical settings and as screening tool for LV systolic
dysfunction. (J Am Coll Cardiol 2007;49:2394–7) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.064(
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whe heart is both a pump and an endocrine organ. Cardiac
tretch and overload stimulate secretion of natriuretic pep-
ides, which have beneficial actions such as vasodilatation
nd natriuresis. B-type natriuretic peptide (BNP) is an
stablished biomarker for diagnosis and risk stratification of
atients with cardiovascular diseases (1).
Studies have explored the role for BNP (and its inactive,
ore stable pro-hormone amino-terminal fragment
-terminal pro-B-type natriuretic peptide [NT-proBNP])
s surrogate markers of left ventricular (LV) systolic dys-
unction (2) and screening tools in patients with dyspnea
rom the *Department of Cardiology, Freeman Hospital, Newcastle-upon-Tyne,
nited Kingdom; †Department of Family and Social Medicine, Albert Einstein
ollege of Medicine of Yeshiva University, Bronx, New York; ‡Department of
ardiovascular Science, Leeds University, Leeds, United Kingdom; and §Freeman
ospital and University of Newcastle, Newcastle-upon-Tyne, United Kingdom. Dr.
earney was supported by an Intermediate Fellow Scholarship from the British Heart
oundation. Dr. Zaman is supported by a Clinical Research Fellowship from the
ritish Heart Foundation.s
Manuscript received November 18, 2006; revised manuscript received February 7,
007, accepted February 12, 2007.3). Elevated concentrations are predictive of poor prognosis
n a variety of cardiovascular diseases (1,4).
Elevated plasma BNP and NT-proBNP in acute coro-
ary syndromes predict mortality independently of LV
ystolic function (5). A strong correlation exists between
NP and extent of reversible ischemia in patients without
V dysfunction (6). This finding and others suggest that
ignificant coronary stenoses per se may cause plasma
atriuretic peptide elevation (7,8). The association of ele-
ated natriuretic peptides with fixed coronary stenoses and
cute cardiac ischemia is recognized (8,9).
We hypothesized that successful percutaneous coronary
evascularization (PCR) would, by removing fixed coronary
tenoses and ischemia, reduce plasma NT-proBNP.
ethods
his study was approved by the Joint Ethics Committee of
ewcastle.
Six hundred and forty-eight patients referred for PCR
ere screened. Of these, 31 patients with angiographically
ignificant (90%) isolated proximal or mid-left anterior
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June 26, 2007:2394–7 Percutaneous Revascularization Reduces BNPescending (LAD) artery stenoses, normal 12-lead electro-
ardiogram, normal resting LV, and normal valvular func-
ion on echocardiography with no history of acute coronary
yndromes were recruited. Urea and creatinine levels were
ithin normal laboratory values. The LAD was chosen for
ts major contribution to LV blood supply in most individ-
als. Patients were excluded if any angiographic disease was
resent in other vessels or in distal LAD.
Having obtained informed consent 2 weeks after cardiac
atheterization (visit 1), all patients had cardiovascular
edications stabilized to prevent possible changes to NT-
roBNP concentrations. After stabilization for a minimum
-week period, patients underwent echocardiography (per-
ormed and reported by a single experienced echocardiog-
apher) to assess resting LV and valvular function (visit 2).
resting, supine plasma NT-proBNP sample was collected
nd stored at 30°C.
Left ventricular systolic function was assessed semiquan-
itatively (10). Left ventricular end-diastolic volume index,
nd-systolic index, ejection fraction, and left atrial size were
ssessed off-line (11) before and after PCR.
Two weeks after second visit, patients were admitted for
CR performed by an experienced operator (A.G.Z.).
atients were prescribed clopidogrel (300 mg once daily)
efore PCR, and continued on 75 mg once daily until study
ompletion. This was the only medication change during
tudy. Lesions were assessed recording fractional flow re-
erve (FFR) using an intracoronary pressure wire (RADI
edical, Uppsala, Sweden). This validated measure defines
hysiologically significant stenoses as FFR of 0.75 after
ntracoronary adenosine injection (140 g) (12). Patients
ith significant stenoses underwent PCR (n  26). Intra-
oronary stents were employed in all and successful PCR
onfirmed by repeat coronary angiography (stenosis 20%)
nd postprocedure FFR of 0.90.
Eight weeks later, with medication unaltered, patients
eturned for resting, supine plasma NT-proBNP (stored at
30°C). Echocardiography was repeated.
T-proBNP assay. Blinded samples were batch-analyzed
sing an electrochemiluminescence immunoassay (Roche
iagnostics Limited, West Sussex, United Kingdom) em-
loying polyclonal antibodies recognizing epitopes located
n the N-terminal part of NT-proBNP. In our laboratory,
he coefficient of variation of measurement for BNP levels
p to 195 pg/ml is 2.9% and for levels of 4,450 pg/ml, 2.3%.
he measuring range is 5 pg/ml to 35,000 pg/ml; therefore
o samples required dilution.
tatistical analysis. Statistical (chi-square) and graphical
normal quartile plot) exploration were performed to assess
t of NT-proBNP variables (before and after) to a log-
ormal distribution. These suggested good fit (not shown),
nd in subsequent analyses, this distribution was assumed.
Analyses were carried out using log transform of NT-
roBNP, but changes in log NT-proBNP correspond to
ultiplicative changes in NT-proBNP itself. For example,
difference of 0.223 in log NT-proBNP reflects a change
A
in NT-proBNP itself by a fac-
or of 1.25 (e0.223). Arithmetic
nd geometric means of NT-
roBNP were calculated before
nd after PCR. The significance
f change in log NT-proBNP
as tested using paired t test.
esults
emographic data are presented
n Table 1. Figure 1 shows
hanges in NT-proBNP.
Of 31 patients identified with
solated angiographically severe
roximal or mid-LAD lesions, 5
ere excluded as FFR was 0.75. Mean preprocedure FFR
as 0.57 and postprocedure 0.92.
Of 26 patients, 24 demonstrated a decrease, 1 an
ncrease, and 1 recorded no change in NT-proBNP after
evascularization.
Pre- and postprocedural mean plasma concentrations of
T-proBNP (pg/ml) for the PCR group were 177.2 and
05.0, respectively. The mean decrease in log NT-proBNP
as 0.533, corresponding to a geometric mean decrease of
T-proBNP by a factor of 59% (95% confidence interval
8.2% to 71.4%, p  0.00005).
There was 1 participant with baseline NT-proBNP levels
xceeding 800 pg/ml. Before logarithmic transformation,
his appeared to be an outlier. Within the log-transformed
ata, however, an appropriate fit on the normal distribution
urve was seen and we, therefore, concluded not a cause for
oncern. Nevertheless, to ensure that results were not driven
y an isolated case, the analysis was repeated excluding this
emographic and Medication Data
Table 1 Demographic and Medication Data
PCR
n  26
Mean age, yrs (SD) 59.3 (10.7)
BMI, kg/m2 28
Current smoker 1
Ex-smoker 17
Hypertension 14
Hypercholesterolemia 18
Diabetes mellitus 6
Aspirin 25
Preprocedure clopidogrel 4
Beta-blockade 18
Statins 23
Calcium antagonists 11
Nicorandil 11
Long-acting oral nitrates 14
ACE inhibitors/ARB 18
Diuretics 4
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
FFR  fractional flow
reserve
LAD  left anterior
descending artery
LV  left ventricular
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
PCR  percutaneous
coronary revascularizationCE  angiotensin-converting enzyme; ARB  angiotens
ndex; PCR  percutaneous coronary revascularization.in receptor blocker; BMI  body mass
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rom that previously reported.
End-diastolic pressures were recorded in 22 patients
efore PCR (range 2 to 15 mm Hg, mean 8.5 mm Hg,
edian 8 mm Hg). No measurements were recorded after
CR. End-diastolic volume index (67.3 mls/m2 vs. 67.4
ls/m2), end-systolic volume index (15.2 mls/m2 vs. 15
ls/m2), ejection fraction (77.5% vs. 77.8%), and left atrial
rea (16.7 cm2 vs. 16.8 cm2) showed no significant change
fter PCR (Wilcoxon signed rank test).
iscussion
ur study suggests that successful PCR of clinically and
hysiologically significant isolated LAD coronary artery
tenoses leads to substantial falls in plasma NT-proBNP
oncentration. The study group was highly selected
therefore small in number) to allow confident localiza-
ion and successful resolution of ischemia territory after
evascularization.
Elevated plasma natriuretic peptides are seen in many
ifferent cardiovascular diseases. The heart is recognized as
n endocrine organ, and natriuretic peptides are used
linically as biochemical markers in heart failure (13).
everal reports identify elevated levels of natriuretic peptides
7,8) and one identifies increased BNP gene expression (14)
n the presence of ischemia. A possible mechanism is
schemia leading to LV dysfunction before an elevation in
Figure 1 Graph of Change in NT-proBNP
Levels Before and 8 Weeks After PCR
NT-proBNP  N-terminal pro-B-type natriuretic peptide;
PCR  percutaneous coronary revascularization.atriuretic peptide concentration. tAfter PCR, studies report changes in atrial natriuretic
eptide levels occurring acutely due to immediate release
rom storage in the stretched atrial wall (15). Measures of
NP concentrations have been reported in the very short
erm after PCR, making it difficult to separate effect of
njury from ischemia resolution on BNP release. Little
nformation exists on long-term influence of revasculariza-
ion of stable ischemic heart disease by PCR on ventricular-
erived natriuretic peptide. Our study differs from others in
important respects:
. Drugs with potential to influence BNP were stabilized
and maintained unchanged after procedure. The only
change was addition of clopidogrel. There are no pub-
lished data to suggest its influence on natriuretic pep-
tides.
. Patients were selected on clinical symptoms, angio-
graphic assessment, and assessment of the physiological
significance of coronary stenosis.
. Timing of repeat samples was based on change in
concentration after surgical revascularization (16) and
need to avoid influence of restenosis (a later phenome-
non) and ischemia recurrence.
mplications for clinical testing. A major issue is the
idespread application of natriuretic peptides assays to identify
V dysfunction. Occult ischemia may have influenced results
n many of the clinical settings in which the assay was
alidated.
Investigators have suggested diastolic dysfunction as the
ause when elevated natriuretic peptides could not be
ttributed to impaired LV systolic function or valvular heart
isease (17). Pathological conditions associated with dia-
tolic dysfunction undoubtedly do raise natriuretic peptides
evels (18). It is acknowledged that ischemia may produce
iastolic dysfunction (19). Thus, it is likely that some cases
f “diastolic dysfunction,” and specifically of elevated natri-
retic peptides in the absence of LV systolic dysfunction or
alvular disease, may result from coronary ischemia. Indeed,
n the first report linking BNP to diastolic dysfunction, all
ubjects had ischemic heart disease (17).
Natriuretic peptides have also been shown to be superior
o LV ejection fraction in risk stratification of patients after
yocardial infarction (20). Elevation of plasma natriuretic
eptide, therefore, may be secondary to significant untreated
oronary disease rather than LV dysfunction. This could
xplain the lack of utility of natriuretic peptide measurement
n identifying specific degrees of LV dysfunction seen in
ome postmyocardial infarction studies (21).
tudy limitations. Interpretation of study data is limited
ue to the small number of selected patients and absence of
ontrol subjects. The ideal group would be identified as
aving significant isolated LAD stenosis with NT-proBNP
easurement before invasive study and repeated at 8 weeks,
ithout PCR. This was not feasible for ethical reasons and
imited numbers. Moreover, the coefficient of variation of
he assay is low, and differences noted in our study are likely
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June 26, 2007:2394–7 Percutaneous Revascularization Reduces BNPo be real. It should be noted, however, that a low coefficient
f variation does not necessarily imply low intraindividual
ariability. This study does not provide evidence of mech-
nism of reduction of NT-proBNP, but the most likely
ause involves alteration of wall stress, which was not
irectly measured.
onclusions
e have demonstrated, in patients with coronary ischemia,
emoval of angiographically and physiologically significant
oronary stenosis results in decrease of plasma NT-proBNP.
ue to the high prevalence of ischemic heart disease, this
nding may have implications for future measurement of
atriuretic peptides in cardiovascular medicine.
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